APR 2021

Volume 7, Issue 4





CELL & GENE THERAPY INSIGHTS

Volume 7, Issue 4

CONTENTS

SPOTLIGHT: Cell therapy CMC and quality control

LATEST ARTICLES

SUPPLY CHAIN CHANNEL EDITION:

Ensuring supply chain scalability for cell and gene therapy products

REPORT: Clinical Trends

Spotlight

Viral vector bioprocessing	
GUEST EDITOR: Christiane Niederlaender, Vice President Technical, Parexel	
FOREWORD Cell therapy CMC and quality control Christiane Niederlaende	571-573
EXPERT INSIGHT The role of big data analytics in digitized manufacturing Damian Marshall, John	571 570
Churchwell & Marc-Olivier Baradei RESEARCH PAPER	449-458
Characterization of a novel high-throughput, high-speed and high-precision plate-based image or ric cell counting method	cytomet-
Jordan Bell, Yongyang Huang, Henry Qazi, Dmitry Kuksin, Jean Qiu, Bo Lin & Leo Li-Ying Chan EXPERT INSIGHT	427-447
Addressing sampling challenges in early phase cell therapy manufacturing Stephanie Mgebroff	
COMMENTARY	459-463
Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measure for cellular therapeutic products Laura Pierce, Sumona Sarkar, Leo Li-Ying Chan, Bo Lin & Jean Qiu	ements
COMMENTARY	551-569
Finding quality in complexity: how cellular therapeutics are shifting analytical paradigms for clinic ply and product manufacturing Vilma Jimenez Sabinina & Dominic Günter Hildebrand	ical sup-

531-549

Volume 7, Issue 4

INTERVIEW Unleashing the full power of next gen bioanalytics on cell therapy development Eric Alonzo 521–530 INTERVIEW Bioprocess and analytics priorities for the tissue engineered product and cell therapy fields Julie Allickson 465–470

Latest article

ROUNDTABLE

Embracing transformation: how big data, AI and digitization are changing cell and gene therapy manufacture

Umay Saplakoglu, Theresa Kotanchek, Damian Marshal, Krishnendu Roy & Scott Sobecki

503-518

Supply Chain Channel

Ensuring supply chain scalability for cell and gene therapy products

INTERVIEW

Building clinical and commercial allogeneic CAR T cell therapy supply chains Bob Amareld

391-397

Report

Clinical Trends

VIEWPOINT

Accelerating the development of novel gene therapies for central nervous system diseases Suyash Prasad

581-589